LOCKPORT, N.Y. — There have been three separate, unrelated cases of rabies in wild animals in the Town of Lockport confirmed by the Niagara County Department of Health on Friday. On Oct. 23 ...

Three cases of rabies have been confirmed in raccoons and a bat that were caught during the past two weeks in the Town of Lockport, the Niagara County Department of Health reported. The first ...

Merck (NYSE:MRK) said a pivotal Phase 3 study for its drug Winrevair in the treatment of pulmonary arterial hypertension, or PAH, has met its primary endpoint. Topline results from the study ...

2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR ...

RAHWAY, N.J., November 19, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK ...

(RTTNews) - Merck & Co., Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Monday positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk ...

Eight months after snaring an inaugural FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 billion Acceleron acquisition. In the phase 3 ZENITH study, Merck’s ...

Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck’s ...

RAHWAY, N.J. - Merck (NS:PROR) & Co., Inc., a leading pharmaceutical company, announced significant progress in its Phase 3 ZENITH study for WINREVAIR (sotatercept-csrk), a treatment for pulmonary ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial.

Second positive phase 3 trial adds to growing body of evidence for WINREVAIR, an activin signaling inhibitor therapy that targets an underlying cause of PAH Merck (NYSE: MRK), known as MSD outside of ...